M.F. Mitwally

No ORCID on file · 23 papers in corpus · active 2002-2010

Study types

  • article 18
  • letter 3
  • book-chapter 1
  • review 1

Condition tags

  • endometriosis 14
  • infertility 5
article 2010
·doi:10.1586/eog.10.10

The third-generation aromatase inhibitor group includes letrozole, and anastrozole and exemestane have both been approved for suppression of estrogen in postmenopausal women with breast cancer. It seems scientifically plausible that various…

article 2009
·doi:10.1016/j.fertnstert.2009.02.047
book-chapter 2008
·doi:10.1017/cbo9780511547287.027

This chapter discusses the potential role of the new group of medications called aromatase inhibitors in assisted reproduction. When an aromatase inhibitor is applied during controlled ovarian hyperstimulation (COO), estrogen production per…

article 2008
·doi:10.1016/j.fertnstert.2008.07.1344
article 2008
·doi:10.1007/s10397-008-0433-7
article 2008
·doi:10.1016/j.fertnstert.2008.07.1343
article 2007
·doi:10.1016/j.fertnstert.2007.07.386
article 2007
·doi:10.1016/j.jmig.2007.06.002
article 2007
Journal of Minimally Invasive Gynecology ·doi:10.1016/j.jmig.2006.07.003
letter 2006
Journal of Minimally Invasive Gynecology ·doi:10.1016/j.jmig.2005.07.006
article 2005
113
·doi:10.1016/j.jmig.2005.07.112
article 2005
230
·doi:10.1016/j.jmig.2005.07.245
article 2005
264
·doi:10.1016/j.jmig.2005.07.244
article 2005
·doi:10.1016/j.fertnstert.2005.07.494
article 2005
·doi:10.1016/j.fertnstert.2005.07.1267
article 2005
·doi:10.1016/j.fertnstert.2005.07.1218
article 2005
·doi:10.1016/j.fertnstert.2005.07.1242
article 2004
Journal of the Society for Gynecologic Investigation ·doi:10.1016/j.jsgi.2004.03.006
article 2004
Fertility and Sterility ·doi:10.1016/j.fertnstert.2003.05.025
letter 2004
Fertility and Sterility ·doi:10.1016/j.fertnstert.2004.04.001
review 2003
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2003.09.008
letter 2003
Fertility and Sterility ·doi:10.1016/s0015-0282(03)02170-8
article 2002
Menopause (New York, N.Y.) ·doi:10.1097/00042192-200207000-00004

OBJECTIVE: To examine the utility of a low-dose estrogen and pulsed progestogen hormone replacement therapy (HRT) regimen for add-back during long-term gonadotropin-releasing hormone-agonist (GnRH-agonist) therapy. DESIGN: A pilot clinical …